Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

EDWARDS LIFESCIENCES CORPORATION

(EW)
  Report
Delayed Nyse  -  04:00 2022-12-02 pm EST
76.55 USD   -1.30%
12/02Wolfe Research Downgrades Edwards Lifesciences to Peer Perform From Outperform
MT
11/28RBC Cuts Price Target on Edwards Lifesciences to $105 From $118 Amid Foreign Exchange Impact on Margins, Keeps Outperform Rating
MT
11/28Edwards Lifesciences Says Tricuspid Valve Replacement Study Showed Survival of 90.1% After One Year
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Truist Securities Lowers Price Target on Edwards Lifesciences to $112 From $117, Keeps Buy Rating

09/22/2022 | 09:35am EST


ę MT Newswires 2022
All news about EDWARDS LIFESCIENCES CORPORATION
12/02Wolfe Research Downgrades Edwards Lifesciences to Peer Perform From Outperform
MT
11/28RBC Cuts Price Target on Edwards Lifesciences to $105 From $118 Amid Foreign Exchange I..
MT
11/28Edwards Lifesciences Says Tricuspid Valve Replacement Study Showed Survival of 90.1% Af..
MT
11/27Edwards announces one-year data on transfemoral transcatheter tricuspid valve replaceme..
PR
11/27Edwards Lifesciences Corporation Announces One-Year Data on Transfemoral Transcatheter ..
CI
11/15Insider Sell: Edwards Lifesciences
MT
11/03Goldman Sachs Adjusts Price Target on Edwards Lifesciences to $73 From $97, Maintains N..
MT
11/01Edwards Lifesciences Launches $750 Million Accelerated Share Repurchase Agreement
MT
11/01Edwards Lifesciences Corp : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
11/01Edwards lifesciences announces $750 million accelerated share repurchase
PR
More news
Analyst Recommendations on EDWARDS LIFESCIENCES CORPORATION
More recommendations
Financials (USD)
Sales 2022 5 359 M - -
Net income 2022 1 495 M - -
Net cash 2022 1 120 M - -
P/E ratio 2022 32,2x
Yield 2022 -
Capitalization 47 328 M 47 328 M -
EV / Sales 2022 8,62x
EV / Sales 2023 7,93x
Nbr of Employees 15 700
Free-Float 95,1%
Chart EDWARDS LIFESCIENCES CORPORATION
Duration : Period :
Edwards Lifesciences Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EDWARDS LIFESCIENCES CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 76,55 $
Average target price 95,32 $
Spread / Average Target 24,5%
EPS Revisions
Managers and Directors
Michael A. Mussallem Chairman & Chief Executive Officer
Scott B. Ullem Chief Financial Officer & Vice President
Todd J. Brinton Chief Scientific Officer & VP-Advanced Technology
Nicholas J. Valeriani Independent Director
Kieran Thomas Gallahue Independent Director
Sector and Competitors
1st jan.Capi. (M$)
EDWARDS LIFESCIENCES CORPORATION-40.91%47 328
THERMO FISHER SCIENTIFIC-15.62%220 754
DANAHER CORPORATION-16.65%199 032
INTUITIVE SURGICAL, INC.-23.60%95 552
BOSTON SCIENTIFIC CORPORATION8.57%64 841
SIEMENS HEALTHINEERS AG-21.63%58 421